- March 12, 2014 - N30 Announces Start of Oral Dosing of N91115 in a Phase 1 Clinical Trial
- October 15, 2013 - N30 Announces Presentations at the 2013 North American Cystic Fibrosis Conference
- April 2, 2013 - N30 Announces Presentation of Preclinical Data at the Basic Science Meeting of the European Cystic Fibrosis Society
- March 13, 2013 - N30 Announces First Patient Treated in Clinical Trial of N6022 in Cystic Fibrosis
- October 8, 2012 - N30 Names Sherif Gabriel, Ph.D. as VP Research
- March 21, 2014 - Primary airway epithelial cells expanded with feeder cells and ROCK inhibitor for screening novel GSNOR inhibitors and CFTR correctorsPrimary airway epithelial cells expanded with feeder cells and ROCK inhibitor for screening novel GSNOR inhibitors and CFTR correctors
- March 21, 2014 - Identification of Novel, Efficacious F508del‐CFTR Correctors to Treat Cystic Fibrosis
- October 14, 2013 - Next generation F508del CFTR correctors using a YFP based high throughput screening assay
- October 14, 2013 - Intestinal Current Measurement to Assess Modulation of F508del-CFTR Function
- October 14, 2013 - A Novel GSNOR Inhibitor with Potent Bronchodilatory Effects and CFTR Potentiation Activity
More posters |
March 21, 2014 Identification of Novel, Efficacious F508del‐CFTR Correctors to Treat Cystic Fibrosis
Xicheng Sun, Jinliang Sui, Jian Qiu, Ramakrishna Boyanapalli, Joan Blonder, Adam Stout, Peter Bove, and Sherif Gabriel
Cystic fibrosis (CF) is a multi‐faceted disease caused by dysfunction of the cystic fibrosis transmembrane conductance regulator (CFTR). The most common mutation, found in 90% of CF patients, is a deletion of phenylalanine at position 508 (F508del‐CFTR). The correctors currently in clinical development targeting CFTR processing may be limited in effectively treating severe CF airways disease.
Therefore, discovery and development of more efficacious correctors of F508del‐CFTR continues to be a critically important goal of the CF community. N30 Pharmaceuticals has developed and begun clinical testing of S‐nitrosoglutathione reductase (GSNOR) inhibitors to treat CF patients.
As part of our continued effort to find a cure for CF, we set about to discover novel, targeted F508del‐CFTR correctors with improved efficacy to be used alone or in combination with our potent GSNOR inhibitors. In this study, we describe new developments in our CFTR corrector program. More…(790Kb)
Comments are closed.
|
- January 24, 2013 - Pharmacological Inhibition of S-Nitrosoglutathione Reductase Improves Endothelial Vasodilatory Function in Rats in vivo
- December 28, 2012 - ADH IB Expression, but Not ADH III, Is Decreased in Human Lung Cancer
- February 15, 2012 - Mechanism of Inhibition for N6022, a First-in-Class Drug Targeting GSNOR
- January 13, 2012 - Structure–activity relationship of pyrrole based GSNOR inhibitors
- August 25, 2011 - Preclinical 28-Day Inhalation Toxicity Assessment of S-Nitrosoglutathione
- July 26, 2011 - Discovery of potent and novel GSNOR inhibitors devoid of cytochrome P450 activities
- April 19, 2011 - Structure–activity relationships of pyrrole based GSNOR inhibitors: Pyrrole regioisomers and propionic acid replacement
|
